Current status of molecular markers for early detection of sporadic pancreatic cancer

Subhankar Chakraborty, Michael J. Baine, Aaron R. Sasson, Surinder Kumar Batra

Research output: Contribution to journalReview article

65 Citations (Scopus)

Abstract

Pancreatic cancer (PC) is a highly lethal malignancy with near 100% mortality. This is in part due to the fact that most patients present with metastatic or locally advanced disease at the time of diagnosis. Significantly, in nearly 95% of PC patients there is neither an associated family history of PC nor of diseases known to be associated with an increased risk of PC. These groups of patients who comprise the bulk of PC cases are termed as "sporadic PC" in contrast to the familial PC cases that comprise only about 5% of all PCs. Given the insidious onset of the malignancy and its extreme resistance to chemo and radiotherapy, an abundance of research in recent years has focused on identifying biomarkers for the early detection of PC, specifically aiming at the sporadic PC cohort. However, while several studies have established that asymptomatic individuals with a positive family history of PC and those with certain heritable syndromes are candidates for PC screening, the role of screening in identifying sporadic PC is still an unsettled question. The present review attempts to assess this critical question by investigating the recent advances made in molecular markers with potential use in the early diagnosis of sporadic PC - the largest cohort of PC cases worldwide. It also outlines a novel yet simple risk factor based stratification system that could be potentially employed by clinicians to identify those individuals who are at an elevated risk for the development of sporadic PC and therefore candidates for screening.

Original languageEnglish (US)
Pages (from-to)44-64
Number of pages21
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1815
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Pancreatic Neoplasms
Early Detection of Cancer
Early Diagnosis
Neoplasms
Radiotherapy
Biomarkers

Keywords

  • Biomarkers
  • Diagnosis
  • PanIN

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Current status of molecular markers for early detection of sporadic pancreatic cancer. / Chakraborty, Subhankar; Baine, Michael J.; Sasson, Aaron R.; Batra, Surinder Kumar.

In: Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1815, No. 1, 01.01.2011, p. 44-64.

Research output: Contribution to journalReview article

Chakraborty, Subhankar ; Baine, Michael J. ; Sasson, Aaron R. ; Batra, Surinder Kumar. / Current status of molecular markers for early detection of sporadic pancreatic cancer. In: Biochimica et Biophysica Acta - Reviews on Cancer. 2011 ; Vol. 1815, No. 1. pp. 44-64.
@article{077b65d27e1548fe827f5c1d7db2f2f5,
title = "Current status of molecular markers for early detection of sporadic pancreatic cancer",
abstract = "Pancreatic cancer (PC) is a highly lethal malignancy with near 100{\%} mortality. This is in part due to the fact that most patients present with metastatic or locally advanced disease at the time of diagnosis. Significantly, in nearly 95{\%} of PC patients there is neither an associated family history of PC nor of diseases known to be associated with an increased risk of PC. These groups of patients who comprise the bulk of PC cases are termed as {"}sporadic PC{"} in contrast to the familial PC cases that comprise only about 5{\%} of all PCs. Given the insidious onset of the malignancy and its extreme resistance to chemo and radiotherapy, an abundance of research in recent years has focused on identifying biomarkers for the early detection of PC, specifically aiming at the sporadic PC cohort. However, while several studies have established that asymptomatic individuals with a positive family history of PC and those with certain heritable syndromes are candidates for PC screening, the role of screening in identifying sporadic PC is still an unsettled question. The present review attempts to assess this critical question by investigating the recent advances made in molecular markers with potential use in the early diagnosis of sporadic PC - the largest cohort of PC cases worldwide. It also outlines a novel yet simple risk factor based stratification system that could be potentially employed by clinicians to identify those individuals who are at an elevated risk for the development of sporadic PC and therefore candidates for screening.",
keywords = "Biomarkers, Diagnosis, PanIN",
author = "Subhankar Chakraborty and Baine, {Michael J.} and Sasson, {Aaron R.} and Batra, {Surinder Kumar}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.bbcan.2010.09.002",
language = "English (US)",
volume = "1815",
pages = "44--64",
journal = "Biochimica et Biophysica Acta - Reviews on Cancer",
issn = "0304-419X",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Current status of molecular markers for early detection of sporadic pancreatic cancer

AU - Chakraborty, Subhankar

AU - Baine, Michael J.

AU - Sasson, Aaron R.

AU - Batra, Surinder Kumar

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Pancreatic cancer (PC) is a highly lethal malignancy with near 100% mortality. This is in part due to the fact that most patients present with metastatic or locally advanced disease at the time of diagnosis. Significantly, in nearly 95% of PC patients there is neither an associated family history of PC nor of diseases known to be associated with an increased risk of PC. These groups of patients who comprise the bulk of PC cases are termed as "sporadic PC" in contrast to the familial PC cases that comprise only about 5% of all PCs. Given the insidious onset of the malignancy and its extreme resistance to chemo and radiotherapy, an abundance of research in recent years has focused on identifying biomarkers for the early detection of PC, specifically aiming at the sporadic PC cohort. However, while several studies have established that asymptomatic individuals with a positive family history of PC and those with certain heritable syndromes are candidates for PC screening, the role of screening in identifying sporadic PC is still an unsettled question. The present review attempts to assess this critical question by investigating the recent advances made in molecular markers with potential use in the early diagnosis of sporadic PC - the largest cohort of PC cases worldwide. It also outlines a novel yet simple risk factor based stratification system that could be potentially employed by clinicians to identify those individuals who are at an elevated risk for the development of sporadic PC and therefore candidates for screening.

AB - Pancreatic cancer (PC) is a highly lethal malignancy with near 100% mortality. This is in part due to the fact that most patients present with metastatic or locally advanced disease at the time of diagnosis. Significantly, in nearly 95% of PC patients there is neither an associated family history of PC nor of diseases known to be associated with an increased risk of PC. These groups of patients who comprise the bulk of PC cases are termed as "sporadic PC" in contrast to the familial PC cases that comprise only about 5% of all PCs. Given the insidious onset of the malignancy and its extreme resistance to chemo and radiotherapy, an abundance of research in recent years has focused on identifying biomarkers for the early detection of PC, specifically aiming at the sporadic PC cohort. However, while several studies have established that asymptomatic individuals with a positive family history of PC and those with certain heritable syndromes are candidates for PC screening, the role of screening in identifying sporadic PC is still an unsettled question. The present review attempts to assess this critical question by investigating the recent advances made in molecular markers with potential use in the early diagnosis of sporadic PC - the largest cohort of PC cases worldwide. It also outlines a novel yet simple risk factor based stratification system that could be potentially employed by clinicians to identify those individuals who are at an elevated risk for the development of sporadic PC and therefore candidates for screening.

KW - Biomarkers

KW - Diagnosis

KW - PanIN

UR - http://www.scopus.com/inward/record.url?scp=78650582001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650582001&partnerID=8YFLogxK

U2 - 10.1016/j.bbcan.2010.09.002

DO - 10.1016/j.bbcan.2010.09.002

M3 - Review article

VL - 1815

SP - 44

EP - 64

JO - Biochimica et Biophysica Acta - Reviews on Cancer

JF - Biochimica et Biophysica Acta - Reviews on Cancer

SN - 0304-419X

IS - 1

ER -